Online citations, reference lists, and bibliographies.
← Back to Search

Persistent Lung Expansion After Pleural Talc Poudrage In Non-surgically Resected Malignant Pleural Mesothelioma.

O. Rena, R. Boldorini, E. Papalia, R. Mezzapelle, G. Baietto, Alberto Roncon, C. Casadio
Published 2015 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
BACKGROUND To investigate the prognostic effect of persistent lung expansion after pleural talcage and other variables in non-surgically resected malignant pleural mesothelioma (MPM) patients. METHODS All consecutive patients submitted to video-assisted thoracoscopic (VAT) pleurodesis by talc poudrage for MPM between 2006 and 2011 were studied. The following parameters were prospectively recorded: age; sex; smoking history; asbestos exposure; C-reactive protein (CRP) levels; platelet (PLT) count; Eastern Cooperative Oncology Group performance status (ECOG PS); histologic subtype; clinical stage (cStage); chemotherapy; pleural fluid volume; and persistence of lung expansion at 3 months follow-up. Survival was assessed in June 2013. RESULTS A total of 172 patients were considered; 146 of 172 patients demonstrated a complete lung expansion at discharge, whereas only 85 of 172 patients had persistent expanded lung on the affected side at the 3-month follow-up chest x-ray. Median survival was 11.5 months (95% confidence interval [CI], 10% to 14%) and 2-year disease-specific survival was 13% (95% CI, 7% to 24%) for the entire cohort. Multivariate analysis showed that non-epithelioid histology (hazard ratio [HR], 2.81; 95% CI, 1.82% to 5.09%), pleural fluid recurrence (HR 2.54; 95% CI, 1.73% to 4.40%), cStage greater than II (HR 2.36; 95% CI, 1.50% to 4.32%), ECOG PS greater than 1 (HR 2.19; 95% CI, 1.26% to 4.23%), CRP greater than 5 mg/L (HR 2.01; 95% CI, 1.18% to 4.12%), and PLT count greater than 400,000 (HR 1.76; 95% CI 1.14% to 3.92%) were independent predictors of poor prognosis. CONCLUSIONS Persistent lung expansion after pleural talc poudrage and absence of fluid recurrence is demonstrated to be a stronger factor in predicting survival rather than clinical stage and other clinical variables in not surgically resected MPM patients.
This paper references
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center
R. Flores (2007)
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
D. Rice (2007)
Pleurodesis outcome in malignant pleural mesothelioma
E. Fysh (2013)
Factors predictive of survival among 337 1183 Ann Thorac Surg RENA ET AL 2015;99:1177–83 MALIGNANT PLEURAL MESOTHELIOMA TREATMENT G E N E R A L T H O R A C IC patients with mesothelioma
JE Herndon (1984)
Is talc pleurodesis safe for young patient following primary spontaneous pneumothorax? Interact Cardiovasc
I Hunt (2007)
Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure.
O. Rena (2012)
Time trend of mesothelioma incidence in the United States and projection of future cases: An update based on SEER data for 1973 through 2005
B. Price (2009)
Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
P. Borasio (2008)
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
A Clinical, Radiographic and Laboratory Evaluation of Prognostic Factors in 363 Patients with Malignant Pleural Mesothelioma
A. C. Tanrıkulu (2010)
Toxicity and response criteria of the Eastern Cooperative Oncology Group
M. Oken (1982)
Invited Commentary (DOI: 10.1007/s00268-004-1046-6)
Carol Tan (2004)
Tumor Type Influences the Effectiveness of Pleurodesis in Malignant Effusions
S. Bielsa (2011)
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: A phase II prospective study
D. Jones (2010)
Management of malignant pleural mesothelioma.
S. West (2006)
Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis.
M. Baud (2013)
Malignant Pleural Mesothelioma: Surgical Management in 285 Patients
P. Bejarano (2009)
Pleural malignant mesothelioma epidemic: Incidence, modalities of asbestos exposure and occupations involved from the Italian National Register
A. Marinaccio (2012)
Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.
T. Yan (2009)
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
J. Edwards (2000)
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
Management of Malignant Mesothelioma by Decortication and Adjunct Phototherapy
C. P. Clarke (2006)
Is talc pleurodesis safe for young patients following primary spontaneous pneumothorax?
I. Hunt (2007)
Survival of pleural malignant mesothelioma in Italy: A population‐based study
F. Montanaro (2009)
Management of malignant pleural effusions.
V. Antony (2001)
Comparison of the Effectiveness of Some Pleural Sclerosing Agents Used for Control of Effusions in Malignant Pleural Mesothelioma: A Review of 117 Cases
A. Şenyiğit (2000)
Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases.
J. Viallat (1996)
Systematic review on pleurectomy/ decortication in the multimodality treatment of malignant pleural mesothelioma
S. Sestini (2014)
TNM Classification of Malignant Tumours
L. Sobin (1987)

This paper is referenced by
Is less also better? A single-institution experience on treatment of early stage Malignant Pleural Mesothelioma.
P. Bertoglio (2017)
ERS/EACTS statement on the management of malignant pleural effusions
A. Bibby (2019)
Survival in patients with malignant pleural effusion undergoing talc pleurodesis.
Maged Hassan (2019)
Predictors of outcome of pleurodesis in patients with malignant pleural effusion: a systematic review and meta-analysis
Maged Hassan (2020)
The role of thoracic surgery in the management of mesothelioma: an expert opinion on the limited evidence
P. Bertoglio (2016)
Diaphragm and lung–preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10‐year experience
M. Ambrogi (2018)
Malignant Pleural Effusion: From Diagnostics to Therapeutics.
R. Asciak (2018)
Talc pleurodesis in malignant pleural effusion: a systematic review and meta-analysis
Eleftherios T. Beltsios (2020)
ERS/EACTS statement on the management of malignant pleural effusions
A. Bibby (2018)
Video-assisted thoracoscopic surgery in the management of mesothelioma
J. Ali (2018)
Pretreatment thrombocytosis as a significant prognostic factor in malignant mesothelioma: a meta-analysis
Y. Zhuo (2017)
Video assisted thoracoscopic and open chest surgery in diagnosis and treatment of malignant pleural diseases.
P. Perikleous (2017)
Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma.
G. Woodard (2020)
Chirurgische Therapie des malignen Pleuramesothelioms
M. Schirren (2016)
Semantic Scholar Logo Some data provided by SemanticScholar